Modality
Gene Therapy
MOA
Menini
Target
HER2
Pathway
T-cell
ALLEoEAsthma
Development Pipeline
Preclinical
~May 2021
→ ~Aug 2022
Phase 1
~Nov 2022
→ ~Feb 2024
Phase 2
May 2024
→ May 2025
Phase 2Current
NCT06957588
2,207 pts·Asthma
2024-05→2025-05·Recruiting
2,207 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-05-2610mo agoPh2 Data· Asthma
2025-10-235mo agoConference· EoE
2026-12-209mo awayAdCom· Asthma
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q4
P2
Recruit…
Catalysts
Ph2 Data
2025-05-26 · 10mo ago
Asthma
Conference
2025-10-23 · 5mo ago
EoE
AdCom
2026-12-20 · 9mo away
Asthma
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06957588 | Phase 2 | Asthma | Recruiting | 2207 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| ROI-9675 | Roivant Sciences | NDA/BLA | HER2 | |
| Olpafutibatinib | Immunocore | Approved | SMN2 | |
| ELV-1411 | Enliven | NDA/BLA | HER2 | |
| TXG-6755 | 10x Genomics | Approved | CD123 | |
| Fixatapinarof | Jiangsu Hengrui | Preclinical | PLK4 |